Aiding in the diagnosis of brain metastases of testicular cancer or extragonadal intracerebral germ cell tumors
Measurement of human chorionic gonadotropin (hCG) is used as an adjunct in the diagnosis of central nervous system (CNS) metastases or recurrence of tumor in patients with germ cell tumors.
Quantitation of the hCG in cerebrospinal fluid (CSF) can be important in guiding treatment and monitoring response to treatment of these tumors.
Measurement of hCG in CSF should not be the only parameter used to determine the presence of CNS metastases in patients with germ cell tumors.
Electrochemiluminescent Immunoassay (ECLIA)
Beta HCG, CSF
Beta-HCG (Beta-Human Chorionic Gonadotropins)
CG (Chorionic Gonadotropins)
Chorionic Gonadotropins, Beta-Subunit (QN), Spinal Fluid
Gonadotropins, Chorionic
hCG, Beta Subunit (Chorionic Gonad)
Human Chorionic Gonadotropins (hCG)
CSF
Patient Preparation: For 12 hours before specimen collection, do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions: Submit specimen from collection vial 1.
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
0.75 mL
Hemolysis | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Ambient | 14 days | ||
Frozen | 14 days |
Aiding in the diagnosis of brain metastases of testicular cancer or extragonadal intracerebral germ cell tumors
Human chorionic gonadotropin (hCG) is synthesized during pregnancy by syncytiotrophoblast cells. hCG may also be produced by neoplastic cells of testicular tumors (seminomas or nonseminomas), ovarian germ cell tumors, gestational trophoblastic disease, choriocarcinoma, and various nontrophoblastic tumors including breast, ovarian, pancreatic, cervical, gastric, and hepatic cancers.
Measurement of hCG is used as an adjunct in the diagnosis of germ cell tumors. The presence of hCG in cerebrospinal fluid (CSF) is suggestive of tumor presence. Pure germinomas are associated with low hCG concentrations in both serum and CSF. A subset of nongerminomatous germ cell tumors contain syncytiotrophoblastic giant cells. These tumors are associated with moderately increased hCG concentrations (<1000 IU/L) in the serum and/or CSF, and the survival rate in patients suffering these tumors is worse than that of patients with pure germinomas. In contrast, choriocarcinomas, another subset of nongerminomatous germ cell tumors, are associated with very high hCG concentrations (>1000 IU/L) in both serum and CSF. Quantification of the hCG in CSF can be important in guiding treatment and monitoring response to treatment of these tumors.
The combination of the specific antibodies used in the Roche Beta hCG immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit.
< or =1.0 IU/L
Elevated levels of human chorionic gonadotropin in spinal fluid indicate the probable presence of central nervous system metastases or recurrence of tumor in patients with germ cell tumors, including patients with testicular cancer or choriocarcinoma.
The use of multivitamins or dietary supplements containing biotin or vitamin B7 that are commonly found in hair, skin and nail supplements and multivitamins can interfere with this test.
In pregnancy, elevations of human chorionic gonadotropin (hCG) in cerebrospinal fluid (CSF) may be observed due to blood contamination during CSF collection.
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Rarely, the presence of antibodies to streptavidin or ruthenium can occur and may interfere in this assay. Caution should be used in interpretation of results and the laboratory should be alerted if the result does not correlate with the clinical presentation.
Values obtained with different assay methods or kits may be different and cannot be used interchangeably.
Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.
Measurement of hCG in CSF should not be relied upon exclusively to determine the presence of central nervous system metastases in patients with germ cell tumors.
1. Tian C, Shi Q, Xiao G, et al: CSF and serum hCG in patients without gestational and neoplastic hCG-secretion. Scand J Clin Lab Invest. 2011 Jul;71(4):264-268
2. Tian C, Shi Q, Pu C, et al: Re-evaluation of the significance of cerebrospinal fluid human chorionic gonadotropin in detecting intracranial ectopic germinomas. J Clin Neurosci. 2011 Feb;18(2):223-226
3. Gonzalez-Sanchez V, Moreno-Perez O, Sanchez Pellicer PS, et al: Validation of the human chorionic gonadotropin immunoassay in cerebrospinal fluid for the diagnostic work-up of neurohypophyseal germinomas. Ann Clin Biochem. 2011 Sep;48(Pt 5):433-437
4. Hu Y, Ni J, Zhang H, et al: An immunoassay for human Chorionic gonadotropin in cerebrospinal fluid: validation of a modified-approved method for accreditation by the College of American Pathologists. J Lab Physicians. 2021 Sep 8;14(1):11-15. doi: 10.1055/s-0041-1733817.
5. Zhang H, Zhang P, Fan J, et al: Determining an optimal cutoff of serum beta-human chorionic gonadotropin for assisting the diagnosis of intracranial germinomas. PLoS One. 2016 Jan 15;11(1):e0147023. doi: 10.1371/journal.pone.0147023
The Roche human chorionic gonadotropin (hCG) assay is a 2-site immunometric sandwich assay using electrochemiluminescence detection. Patient specimen, biotinylated monoclonal hCG-specific antibody, and monoclonal hCG-specific antibody labeled with a ruthenium react to form a complex. Streptavidin-coated microparticles act as the solid phase to which the complex becomes bound. Voltage is applied to the electrode inducing a chemiluminescent emission from the ruthenium, which is then measured against a calibration curve to determine the amount of hCG in the patient specimen.(Package insert: Elecsys HCG+B. Roche Diagnostics; V1.0. 10/2020)
Monday through Saturday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
84702
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
BHSF | Chorionic Gonad Beta-Subunit QN,CSF | 14041-8 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
BHSF | Chorionic Gonad Beta-Subunit QN,CSF | 14041-8 |